Lead
On Thursday, Dec. 4, 2025, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) postponed a contentious vote at CDC headquarters in Atlanta that would have reconsidered the long-standing recommendation to give hepatitis B vaccine to all newborns. Committee members cited shifting language in the ballot and insufficient time to review multiple revisions, and the vote was moved to the following day. The meeting featured unusually sharp disagreement among advisers and raised questions about procedure and trust in the advisory process. The delay adds a packed agenda for Friday and leaves the future of the universal newborn dose unresolved for now.
Key takeaways
- ACIP postponed votes on Dec. 4, 2025, moving a decision on universal newborn hepatitis B vaccination to Dec. 5, 2025 after last-minute changes to the ballot language.
- Committee members reported receiving three different versions of the voting questions within 72 hours, prompting concerns about the integrity of the process.
- The current U.S. recommendation calls for universal hepatitis B vaccination at birth to prevent perinatal and early-life infection, which carries a much higher risk of chronic liver disease, cancer, and death.
- Speakers at the meeting were sharply divided: some, including an acting FDA representative, questioned the necessity of the universal birth dose for low-risk infants; others defended the policy as central to decades-long elimination efforts in the U.S.
- Nonvoting liaisons from major medical groups criticized the procedure and warned of ethical and equity implications if decisions are made without comprehensive risk–benefit analysis.
- The committee will also address how the U.S. immunization schedule compares with other countries and examine proposed links between aluminum adjuvants and asthma at upcoming sessions.
- Public-health experts warn that changing the recommendation could reduce vaccine access and coverage, with downstream effects on insurance reimbursement and clinical practice.
Background
Hepatitis B is a virus that targets the liver and can be transmitted sexually, through injection drug use, and from mother to infant at birth. Infants infected perinatally have a far higher likelihood of chronic infection, which significantly raises lifetime risks of cirrhosis, liver cancer and premature death. Because infections acquired in infancy are so likely to become chronic, U.S. public-health policy established a universal newborn dose decades ago to close gaps in maternal screening and protect all children.
ACIP is the federal advisory group whose recommendations shape clinician practice and influence insurance coverage for vaccines in the United States. Its guidance has been central to the nation’s multi-decade strategy to drive hepatitis B incidence to very low levels. Historically the committee has worked closely with professional medical societies and CDC experts to develop policy; members and liaisons told the Dec. 4 session that recent procedural changes and turnover on the committee have strained those relationships.
Main event
The meeting at CDC headquarters in Atlanta began with routine agenda items but quickly devolved into procedural disputes when the language of the hepatitis B vote changed during the day. Several voting members — including Dr. Joseph Hibbeln — objected that they had been given multiple versions of the question in a short period, leaving inadequate time for considered review. The committee elected to defer the votes until Friday to allow written review of the final language.
Discussion at the meeting revealed a sharp split. Dr. Tracy Beth Høeg, representing the Food and Drug Administration and newly named acting director of the FDA’s Center for Drug Evaluation and Research, questioned whether a universal birth dose remains necessary for infants without known maternal or household risk. Opponents of change argued that the current blanket policy prevents missed cases and has demonstrably reduced disease in the U.S.
Dr. Cody Meissner, a longtime pediatrician and current ACIP member, defended the universal approach by pointing to the decline in disease under the existing program. In contrast, several nonvoting liaisons and some advisers said the committee’s process deviated from normal practice and did not sufficiently weigh harms, benefits and equity concerns before advancing such a consequential change.
The postponement left several consequential items on Friday’s calendar beyond the hepatitis B vote: a formal comparison of the U.S. immunization schedule with those of other nations and a review of evidence regarding aluminum-containing vaccine adjuvants and asthma. Many professional groups have said there is no robust evidence that aluminum adjuvants are unsafe, but the issue was added to the agenda amid heightened scrutiny of vaccine components.
Analysis & implications
A change to the universal newborn hepatitis B recommendation would have immediate clinical and policy consequences. Clinicians use ACIP guidance to set practice; payers often align reimbursement with that guidance. Narrowing the recommendation to a risk-based or maternal-status-based approach could complicate newborn care, require additional maternal testing and create opportunities for missed doses at the point of delivery.
From an equity perspective, universal newborn vaccination has functioned as a safety net for infants whose mothers lack prenatal care or whose hepatitis B status is unknown. Targeted strategies can perform well when systems reliably identify all at-risk births, but real-world gaps in testing and follow-up mean selective approaches risk leaving vulnerable infants unprotected.
The procedural dispute itself carries political and institutional ramifications. ACIP’s perceived independence and deliberative norms underpin trust in its guidance; rapid turnovers in membership or abrupt changes to question language can erode that trust among professional societies, clinicians and the public. If stakeholder groups withdraw technical collaboration, the committee may face greater criticism and reduced legitimacy for its recommendations.
Internationally, some high-income countries use different schedules, and domestic policy makers often point to those differences in debates. However, direct comparisons require caution because countries vary in hepatitis B prevalence, prenatal screening practices and healthcare access. Any policy shift in the U.S. would need to consider those contextual differences and model likely outcomes for infection, chronic disease and health inequities.
Comparison & data
| Jurisdiction | Newborn (birth) hepatitis B dose |
|---|---|
| United States | Universal newborn dose (current recommendation) |
| Many high‑income countries | Often rely on maternal screening and selective neonatal dosing or schedule-dose later in infancy |
The table summarizes broad policy patterns rather than a comprehensive country-by-country inventory. Public-health experts note that some peer countries prioritize maternal screening combined with selective neonatal dosing; others incorporate the birth dose into routine schedules. Any direct policy transfer requires evaluation of local prenatal screening coverage, healthcare delivery at birth, and population prevalence of hepatitis B.
Reactions & quotes
Several committee members and liaisons publicly criticized the process and voiced concerns that rapid changes to voting language compromised careful analysis. Below are representative statements recorded during the meeting with brief context.
“This is the third version of the questions that we have received in 72 hours, and we’re trying to evaluate a moving target.”
Dr. Joseph Hibbeln, ACIP voting member
Hibbeln raised procedural objection to multiple ballot revisions over three days, arguing the pace prevented adequate written review and informed deliberation.
“For babies without high risk factors… the potential for benefit is so low. Why are we stating that it is absolutely necessary to give this dose at birth, when high income nations throughout the world are not?”
Dr. Tracy Beth Høeg, FDA representative
Høeg, speaking in her new role at the FDA’s Center for Drug Evaluation and Research, questioned whether the universal birth dose remains warranted for low-risk infants and cited international practice differences.
“As physicians, your ethical obligation is to ‘first, do no harm’ and you are failing in that by promoting this anti-vaccine agenda without the data and evidence necessary to make those informed decisions.”
Dr. Jason Goldman, liaison for the American College of Physicians
Goldman, a nonvoting liaison, criticized the committee’s process and urged a more thorough assessment of harms, benefits and equity before any change is made.
Unconfirmed
- Allegations that the meeting’s changes are part of a coordinated campaign to systematically undermine vaccine access were raised by experts but remain unproven and are based on interpretation rather than direct documentary evidence.
- Reports that ACIP membership was replaced in June with a single actor’s slate are reported in media accounts; fuller documentation of how that turnover affected deliberations and trust is incomplete and contested.
- Claims that aluminum adjuvants definitively cause asthma were discussed on the agenda, but current mainstream scientific reviews do not support a causal link; the committee’s pending review will examine the evidence.
Bottom line
The December 4 meeting exposed both substantive disagreement about the value of a universal newborn hepatitis B dose for low-risk infants and deep procedural concerns among advisers and liaisons. Postponing the vote gives ACIP members time to review final ballot language, but does not resolve the underlying policy or trust issues raised during the session.
Any change to the recommendation would carry clinical, equity and coverage implications and is likely to prompt further scrutiny from professional societies and public-health authorities. Observers should watch Friday’s meeting for whether the committee adopts clarified language, how it addresses evidence gaps, and whether major professional groups will re-engage in the advisory process.